OpenAccess: Closed

This work is not Open Acccess. We may still have a PDF, if this is the case there will be a green box below.

Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial

Andrew Blauvelt,Jonathan I. Silverberg,Charles Lynde,Thomas Bieber,Samantha Eisman,Jacek Zdybski,Walter Gubelin,Eric L. Simpson,Fernando Valenzuela,Paulo Ricardo Criado,Mark Lebwohl,Claire Feeney,Tahira Khan,Pinaki Biswas,Marco DiBonaventura,Hernán Valdez,Michael C. Cameron,Ricardo Rojo

Medicine

Atopic dermatitis

Eczema Area and Severity Index

2022

Cite this:

Generate Citation

“Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial” is a paper by Andrew Blauvelt Jonathan I. Silverberg Charles Lynde Thomas Bieber Samantha Eisman Jacek Zdybski Walter Gubelin Eric L. Simpson Fernando Valenzuela Paulo Ricardo Criado Mark Lebwohl Claire Feeney Tahira Khan Pinaki Biswas Marco DiBonaventura Hernán Valdez Michael C. Cameron Ricardo Rojo published in 2022. It has an Open Access status of “closed”. You can read and download a PDF Full Text of this paper here.